Cancer Combination Therapies by Angiogenesis Inhibitors; a Comprehensive Review

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2022 Apr 8

PMID 35392964

Authors

Mohammad Javed Ansari

Dmitry Bokov

Alexander Markov

Abduladheem Turki Jalil

Mohammed Nader Shalaby

Wanich Suksatan

Supat Chupradit

Hasan S Al-Ghamdi

Navid Shomali

Amir Zamani

Ali Mohammadi

Mehdi Dadashpour

Affiliations

Soon will be listed here.

Abstract

Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and activation. Owing to this fact, angiogenesis blockade therapy was established to fight cancer by eliminating the nutrient and oxygen supply to the malignant cells by impairing the vascular network. Given the dominant role of vascular-endothelium growth factor (VEGF) in the angiogenesis process, the well-known anti-angiogenic agents mainly depend on the targeting of its actions. However, cancer cells mainly show resistance to anti-angiogenic agents by several mechanisms, and also potentiated local invasiveness and also distant metastasis have been observed following their administration. Herein, we will focus on clinical developments of angiogenesis blockade therapy, more particular, in combination with other conventional treatments, such as immunotherapy, chemoradiotherapy, targeted therapy, and also cancer vaccines. Video abstract.

Citing Articles

Alda‑1 restores ALDH2‑mediated alcohol metabolism to inhibit the NF‑κB/VEGFC axis in head and neck cancer.

Lin Y, Lee Y, Liao J, Yu P, Chou C, Yang Y Int J Mol Med. 2025; 55(4).

PMID: 39886980 PMC: 11819766. DOI: 10.3892/ijmm.2025.5496.

Modeling of chemo-radiotherapy targeting growing vascular tumors: A continuum-level approach.

Lampropoulos I, Koutsi M, Kavousanakis M PLoS One. 2025; 20(1):e0301657.

PMID: 39813216 PMC: 11734981. DOI: 10.1371/journal.pone.0301657.

A Novel Cell-Penetrating Peptide-Vascular Endothelial Growth Factor Small Interfering Ribonucleic Acid Complex That Mediates the Inhibition of Angiogenesis by Human Umbilical Vein Endothelial Cells and in an Ex Vivo Mouse Aorta Ring Model.

Kim M, Park S, Kim S, Seo J, Roh S Biomater Res. 2025; 29():0120.

PMID: 39780959 PMC: 11704089. DOI: 10.34133/bmr.0120.

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.

Liu J, Zhang J, Li H, Song G, Di L, Jiang H BMC Cancer. 2025; 25(1):9.

PMID: 39754078 PMC: 11697748. DOI: 10.1186/s12885-024-13403-2.

The metastatic cascade through the lens of therapeutic inhibition.

Miranda I, Jahan N, Shevde L Cell Rep Med. 2024; 6(1):101872.

PMID: 39706193 PMC: 11866422. DOI: 10.1016/j.xcrm.2024.101872.

References

Chadha A, Skinner H, Gunther J, Munsell M, Das P, Minsky B . Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910. PMC: 4919049. DOI: 10.1371/journal.pone.0156910. View

Nooka A, Wang M, Yee A, Kaufman J, Bae J, Peterkin D . Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018; 4(12):e183267. PMC: 6440721. DOI: 10.1001/jamaoncol.2018.3267. View

Li J, Cong L, Liu J, Peng L, Wang J, Feng A . The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol. 2020; 10:594125. PMC: 7689210. DOI: 10.3389/fonc.2020.594125. View

Thomas A, Trarbach T, Bartel C, Laurent D, Henry A, Poethig M . A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol. 2007; 18(4):782-8. DOI: 10.1093/annonc/mdl469. View

Huang Q, Duan L, Qian X, Fan J, Lv Z, Zhang X . IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma. Sci Rep. 2016; 6:36551. PMC: 5098156. DOI: 10.1038/srep36551. View

Chung A, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D . Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 2012; 227(4):404-16. DOI: 10.1002/path.4052. View

Yang K, Chi M, Ko H, Huang Y, Huang S, Lin Y . Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol. 2021; 16(1):18. PMC: 7819176. DOI: 10.1186/s13014-020-01742-w. View

Verdaguer H, Tabernero J, Macarulla T . Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016; 8(3):230-42. PMC: 4872251. DOI: 10.1177/1758834016635888. View

De Rosa L, Di Stasi R, DAndrea L . Pro-angiogenic peptides in biomedicine. Arch Biochem Biophys. 2018; 660:72-86. DOI: 10.1016/j.abb.2018.10.010. View

10.

Murata R, Nishimura Y, Hiraoka M . An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys. 1997; 37(5):1107-13. DOI: 10.1016/s0360-3016(96)00628-1. View

11.

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

12.

Formenti S, Demaria S . Systemic effects of local radiotherapy. Lancet Oncol. 2009; 10(7):718-26. PMC: 2782943. DOI: 10.1016/S1470-2045(09)70082-8. View

13.

Poole R, Vaidya A . Ramucirumab: first global approval. Drugs. 2014; 74(9):1047-58. DOI: 10.1007/s40265-014-0244-2. View

14.

Spano J, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C . Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008; 371(9630):2101-8. DOI: 10.1016/S0140-6736(08)60661-3. View

15.

Schmidinger M . Third-line dovitinib in metastatic renal cell carcinoma. Lancet Oncol. 2014; 15(3):245-6. DOI: 10.1016/S1470-2045(14)70082-8. View

16.

Jiang B, Agani F, Passaniti A, Semenza G . V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997; 57(23):5328-35. View

17.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K . Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019; 12(1):27. PMC: 6417086. DOI: 10.1186/s13045-019-0718-5. View

18.

Jiang X, Guan W, Li M, Liang W, Qing Y, Dai N . Endostatin combined with platinum-based chemo-radiotherapy for advanced non-small cell lung cancer. Cell Biochem Biophys. 2014; 71(2):571-7. DOI: 10.1007/s12013-014-0236-6. View

19.

Teleanu R, Chircov C, Grumezescu A, Teleanu D . Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med. 2020; 9(1). PMC: 7020037. DOI: 10.3390/jcm9010084. View

20.

Kelly R, Rixe O . Axitinib (AG-013736). Recent Results Cancer Res. 2010; 184:33-44. DOI: 10.1007/978-3-642-01222-8_3. View